Screener
Ionis Pharmaceuticals IONS Short-Term Borrowings
Short-Term Borrowings at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ConvertibleDebtCurrent.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued compensation | 50,293 | 116,236 |
| Accrued liabilities | 115,778 | 106,089 |
| Income taxes payable | 2,877 | 2,713 |
| 0 percent convertible senior notes due April 2026, net | - | 431,948 |
| Current portion of deferred contract revenue | 73,837 | 73,761 |
| Other current liabilities | 25,149 | 22,738 |
| Total current liabilities | 315,638 | 781,567 |
| Long-term deferred contract revenue | 63,030 | 92,001 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's short-term borrowings?
- Ionis Pharmaceuticals (IONS) reported short-term borrowings of $0 in Q2 2026.
- How has Ionis Pharmaceuticals's short-term borrowings changed year-over-year?
- Ionis Pharmaceuticals's short-term borrowings decreased by 100.0% year-over-year, from $630.12M to $0.
- What is the long-term trend for Ionis Pharmaceuticals's short-term borrowings?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's short-term borrowings has grown at a 8.1% compound annual growth rate (CAGR), from $293.16M to $431.95M.
- What does short-term borrowings mean?
- Bank lines of credit, revolving credit facilities, and other short-term debt instruments with maturities under one year.
Ask your AI about Ionis Pharmaceuticals's short-term borrowings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude